Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Taldefgrobep Alfa in Participants With Spinal Muscular Atrophy [Phase 3]

View source ↗

Summary

This is an update on a Phase 3 trial evaluating Taldefgrobep Alfa for Spinal Muscular Atrophy, with the study currently active and not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• Taldefgrobep alfa (taldefgrobep alfa)

Snippet

Sponsor: Biohaven Pharmaceuticals, Inc. | Conditions: Spinal Muscular Atrophy, Neuromuscular Diseases | Phase 3 | Status: ACTIVE_NOT_RECRUITING